Histone deacetylase (HDAC) inhibitor LBH589 increases duration of γ-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

被引:142
|
作者
Geng, Ling
Cuneo, Kyle C.
Fu, Allie
Tu, Tianxiang
Atadja, Peter W.
Hallahan, Dennis E.
机构
[1] Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA
[4] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[5] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN USA
[6] Novartis Inst Biomed Res Inc, Cambridge, MA USA
关键词
D O I
10.1158/0008-5472.CAN-06-0049
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histone deacetylases (HDAC) have been identified as therapeutic targets due to their regulatory function in DNA structure and organization. LBH589 is a novel inhibitor of class I and 11 HDACs. We studied the effect of LBH589 and ionizing radiation (IR) on DNA repair in two human nonsmall cell lung cancer (NSCLC) cell lines (H23 and H460). gamma-H2AX foci present at DNA double-strand breaks (DSBs) were detected in the nuclei following 3 Gy irradiation for up to 6 hours. LBH589 administered before irradiation increased the duration of gamma-H2AX foci beyond 24 hours. Furthermore, radiation alone induced translocation of HDAC4 to the nucleus. In contrast, treatment with LBH589 followed by irradiation resulted in HDAC4 confinement to the cytoplasm, indicating that HDAC inhibition affects the nuclear localization of HDAC4. The findings that LBH589 confines HDAC4 to the cytoplasm and increases the duration of gamma-H2AX foci in irradiated cell lines suggest that HDAC4 participates in DNA damage signaling following IR. Annexin-propidium iodide flow cytometry assays, cell morphology studies, and cleaved caspase-3 Western blot analysis revealed a synergistic effect of LBB589 with IR in inducing apoptosis. Clonogenic survival showed a greater than additive effect when LBH589 was administered before irradiation compared with irradiation alone. In vivo tumor volume studies showed a growth delay of 20 days with combined treatment compared with 4 and 2 days for radiation or LBH589 alone. This study identifies HDAC4 as a biomarker of LBH589 activity and recognizes the ability of LBH589 to sensitize human NSCLC to radiation-induced DNA DSBs.
引用
收藏
页码:11298 / 11304
页数:7
相关论文
共 33 条
  • [1] Histone deacetylase inhibitor LBH589 increases the duration of radiation induced γH2AX foci and confines HDAC4 to the cytoplasm in two human lung cancer cell lines
    Cuneo, Kyle C.
    Fu, Allie
    Hallahan, Dennis E.
    Geng, Ling
    CANCER RESEARCH, 2006, 66 (08)
  • [2] Histone deacetylase inhibitor LBH589 radiosensitizes non-small cell lung cancer by inhibiting DNA repair
    Cuneo, K. C.
    Fu, A.
    Hallahan, D. E.
    Geng, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S158 - S158
  • [3] The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
    Crisanti, M. Cecilia
    Wallace, Africa F.
    Kapoor, Veena
    Vandermeers, Fabian
    Dowling, Melissa L.
    Pereira, Luana P.
    Coleman, Kara
    Campling, Barbara G.
    Fridlender, Zvi G.
    Kao, Gary D.
    Albelda, Steven M.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (08) : 2221 - 2231
  • [4] A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer
    de Marinis, Filippo
    Atmaca, Akin
    Tiseo, Marcello
    Giuffreda, Libero
    Rossi, Antonio
    Gebbia, Vittorio
    D'Antonio, Chiara
    Dal Zotto, Laura
    Al-Batran, Salah-Eddin
    Marsoni, Silvia
    Wolf, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (08) : 1091 - 1094
  • [5] Priming of non-small cell lung cancer (NSCLC) cell lines to erlotinib by the histone deacetylase (HDAC) inhibitor panobinostat
    Greve, G.
    Schiffmann, I.
    Luebbert, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 67 - 67
  • [6] Phase I trial of the HDAC inhibitor LBH589 in combination with sorafenib in patients with renal cell carcinoma, non-small cell lung cancer and soft tissue sarcomas.
    Butler, Charles Mackie
    Laboccetta, Lydia T.
    Brisendine, Alan
    Keane, Thomas E.
    Sherman, Carol Arthur
    Drabkin, Harry A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [7] THE PREVALENCE OF HISTONE DEACETYLASE (HDAC) EXPRESSION IN KOREAN NON-SMALL CELL LUNG CANCER PATIENTS
    Baek, Heejong
    Koh, Jae-Soo
    Kim, Chul H.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1048 - S1048
  • [8] Comparison of anticancer effects of a novel histone deacetylase (HDAC) inhibitor CG200745 and SAHA in non-small lung cancer cells
    Kim, Hak-Ryul
    Jung, Jae-Wan
    Hwang, Ki-Eun
    Park, Chul
    Jeong, Eun-Taik
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [9] Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)
    Zang, Hongjing
    Qian, Guoqing
    Zong, Dan
    Fan, Songqing
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Sun, Shi-Yong
    CANCER, 2020, 126 (09) : 2024 - 2033
  • [10] Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC)
    Gerber, David E.
    Skelton, Rachael
    Dong, Ying
    Loudat, Laurin
    Dowell, Jonathan
    Boothman, David A.
    Sarode, Venetia
    Zhang, Wei
    Xie, Yang
    Gazdar, Adi
    Frenkel, Eugene P.
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)